| What is the purpose of the orphan drug act? M Herder PLoS medicine 14 (1), e1002191, 2017 | 94 | 2017 |
| Pharmaceutical drugs of uncertain value, lifecycle regulation at the US Food and Drug Administration, and institutional incumbency M Herder The Milbank Quarterly 97 (3), 820-857, 2019 | 44 | 2019 |
| Reflections on the commercialization of research conducted in public institutions in Canada J Downie, M Herder McGill Health L. Publ'n 1, 23, 2007 | 41 | 2007 |
| From discovery to delivery: public sector development of the rVSV-ZEBOV Ebola vaccine M Herder, JE Graham, R Gold Journal of Law and the Biosciences 7 (1), lsz019, 2020 | 34 | 2020 |
| When everyone is an orphan: against adopting a US-styled orphan drug policy in Canada M Herder Accountability in research 20 (4), 227-269, 2013 | 32 | 2013 |
| Transparency of regulatory data across the European medicines agency, health Canada, and US food and Drug Administration AC Egilman, A Kapczynski, ME McCarthy, AT Luxkaranayagam, ... Journal of Law, Medicine & Ethics 49 (3), 456-485, 2021 | 28 | 2021 |
| A responsibility to commercialize? Tracing academic researchers’ evolving engagement with the commercialization of biomedical research K Holloway, M Herder Journal of responsible innovation 6 (3), 263-283, 2019 | 23 | 2019 |
| Unlocking Health Canada’s cache of trade secrets: mandatory disclosure of clinical trial results M Herder CMAJ 184 (2), 194-199, 2012 | 23 | 2012 |
| Canada’s stem cell corporation: Aggregate concerns and the question of public trust M Herder, JD Brian Journal of Business Ethics 77, 73-84, 2008 | 22 | 2008 |
| Regulating prescription drugs for patient safety: Does Bill C-17 go far enough? M Herder, E Gibson, J Graham, J Lexchin, B Mintzes CMAJ 186 (8), E287-E292, 2014 | 21 | 2014 |
| Patents & (and) the Progress of Personalized Medicine: Biomarkers Research as Lens M Herder Annals Health L. 18, 187, 2009 | 19 | 2009 |
| Policy design for human embryo research in Canada: A history (Part 1 of 2) F Baylis, M Herder Journal of Bioethical Inquiry 6, 109-122, 2009 | 18 | 2009 |
| Asking for Money Back-Chilling Commercialization or Recouping Public Trust in the Context of Stem Cell Research? M Herder Colum. Sci. & Tech. L. Rev. 9, 203, 2008 | 18 | 2008 |
| From sandbox to pandemic: Agile reform of Canadian drug regulation IE Vural, M Herder, JE Graham Health Policy 125 (9), 1115-1120, 2021 | 17 | 2021 |
| Exploring the Food and Drug Administration’s review and approval of Entresto (sacubitril/valsartan) AL Eadie, KR Brunt, M Herder Pharmacology Research & Perspectives 9 (3), e00794, 2021 | 16 | 2021 |
| Regulators, pivotal clinical trials, and drug regulation in the age of COVID-19 J Lexchin, J Graham, M Herder, T Jefferson, T Lemmens International Journal of Health Services 51 (1), 5-13, 2021 | 16 | 2021 |
| Toward a jurisprudence of drug regulation M Herder The Journal of Law, Medicine & Ethics 42 (2), 244-262, 2014 | 16 | 2014 |
| The role of biotechnology intellectual property rights in the bioeconomy of 2030 ER Gold, M Herder, M Trommetter Report prepared for OECD International Futures Program. Paris, France: OECD, 2007 | 16 | 2007 |
| Fair pricing of “old” orphan drugs: considerations for Canada’s orphan drug policy EA Roberts, M Herder, A Hollis Cmaj 187 (6), 422-425, 2015 | 14 | 2015 |
| Proliferating patent problems with human embryonic stem cell research? M Herder Journal of Bioethical Inquiry 3, 69-79, 2006 | 14 | 2006 |
